Skip to main content
Premium Trial:

Request an Annual Quote

Cell Signaling Technology to Conduct Biomarker Study for Aventis

NEW YORK, Sept. 21 (GenomeWeb News) - Cell Signaling Technology said today that it has signed an agreement with Aventis to conduct a pilot study in which CST will identify phosphorylation sites and prospective biomarkers of protein tyrosine kinase targets for Aventis.

 

Under the terms of the agreement, CST, based in Beverly, Mass., will use its PhosphoScan technology to identify the biomarkers, which may enable target validation and profiling assays to monitor kinase-targeted therapeutic pharmacodynamics and efficacy, CST said.

 

PhosphoScan, according to the company, is patent-pending phospho-proteomics technology that combines immunoaffinity purification and mass spectroscopy to determine cellular PTK phosphorylation profiles.

 

Financial terms of the deal were not disclosed.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.